Pharmaceutical News

RSS

FDA, USP co-sponsors OTC drug products workshop

Updated public standards incorporating new tests for impurities as well as more modern technologies to help ensure the quality of over-the-counter (OTC) ingredients and products will be key areas of focus for a September 8-9, 2011, workshop co-sponsored by the U.S. Food & Drug Administration (FDA) and the U.S. Pharmacopeial Convention.

17 Aug 2011

PAREXEL recognized as Company of the Year for the Pharmaceutical Industry

PAREXEL International Corporation, a leading global biopharmaceutical services provider, has been named Company of the Year for the Pharmaceutical Industry in The Eighth Annual International Business Awards, the only global, all-encompassing business awards program honoring great performances in business.

From Parexel 17 Aug 2011

Bayer Healthcare to provide over 600,000 moxifloxacin tablets to fight MDR-TB in China

Bayer Healthcare announced on Monday it "has agreed to support the World Health Organization (WHO) and the Stop TB Partnership in the fight against multidrug-resistant tuberculosis (MDR-TB) by making 620,000 tablets of the antibiotic moxifloxacin available to WHO," according to a Bayer press release.

17 Aug 2011

Study finds broadest immune response from LAIV nasal spray vaccines for children

Children younger than 3 years old receive the same protective antibody response from the recommended two doses of licensed seasonal influenza vaccines regardless of whether the two doses are injected by needle, inhaled through a nasal spray or provided through one dose of each in any order, according to researchers funded by the National Institutes of Health.

17 Aug 2011

FDA approves two new strengths of Lupron Depot-PED for central precocious puberty

Abbott announced today that the U.S. Food and Drug Administration has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the treatment of children with central precocious puberty (CPP).

17 Aug 2011

Inflammation linked with RA increases patients risk of heart disease

Rheumatoid arthritis (RA) sufferers are at an increased risk of dying due to cardiovascular disease. A new five year study published in BioMed Central's open access journal Arthritis Research & Therapy showed that the risk of cardiovascular disease for people with RA is due to disease-related inflammation as well as the risk factors which affect the general population.

16 Aug 2011

Scientists demonstrate how Modified Citrus Pectin enhances immune function

Groundbreaking research demonstrates the ability of a specific form of Modified Citrus Pectin (MCP) to greatly enhance immune function.

16 Aug 2011

AHRQ's new Spanish-language guide on heart medications

A free, illustrated easy-to-read pamphlet that compares drugs for preventing heart attacks, heart failure or strokes in people with stable coronary heart disease is one of six new Spanish-language publications from HHS' Agency for Healthcare Research and Quality that help patients compare treatments for common illnesses.

16 Aug 2011

Combination immunotherapy more effective for patients with Sezary Syndrome

A three-pronged immunotherapy approach nearly doubles five-year survival among patients with rare leukemic form of cutaneous T-cell lymphoma, reports a new study by dermatologists from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania.

16 Aug 2011

Starpharma starts bacterial vaginosis prevention study of VivaGel

Starpharma Holdings Limited today announced the commencement of its Phase 2 study of VivaGel for the prevention of bacterial vaginosis (BV), following receipt of ethics approval.

15 Aug 2011

NAI reaches settlement with VPX over beta-alanine patent litigation

Natural Alternatives International, Inc., a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced that it reached a settlement with one of the defendants to litigation pending before the U.S. District Court for the District of Delaware, Vital Pharmaceutical, Inc..

12 Aug 2011

Thorne acquires global rights to Q-Cell, an advanced formulation Coenzyme Q10

Thorne Research, Inc., a leader in developing and manufacturing pure, high quality nutritional supplements marketed through licensed healthcare practitioners, has acquired exclusive global rights to market Q-Cell, an advanced formulation Coenzyme Q10 (CoQ10) supplement formerly marketed under the brand name Q-Best.

12 Aug 2011

Fibrate drugs may not prevent heart attacks in diabetes patients with elevated cholesterol

Type 2 diabetes patients, who face higher risk of cardiovascular disease, often take a combination of medications designed to lower their LDL or "bad" cholesterol and triglyceride levels while raising their HDL or "good" cholesterol because doctors long have thought that taken together, the drugs offer protection from heart attacks and improve survival.

12 Aug 2011

Benefits of nanoparticle sunscreens outweigh risks

The most personal encounter that many consumers have had so far with the much-heralded field of nanotechnology is the topic of an article in the current edition of Chemical & Engineering News (C&EN), the American Chemical Society's weekly newsmagazine.

12 Aug 2011

Advaxis completes ADXS-PSA prostate cancer construct pre-IND meeting with the FDA

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has completed a pre-IND (Investigational New Drug) meeting with the FDA on August 10 to discuss the development plan for ADXS-PSA, a construct for the treatment of prostate cancer.

12 Aug 2011

Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis

For nearly 60 years, Pyrazinamide (PZA) has been used in conjunction with other medications to treat tuberculosis (TB), but scientists did not fully understand how the drug killed TB bacteria. PZA plays a unique role in shortening the duration of current TB therapy to six months and is used frequently to treat multi-drug resistant TB.

12 Aug 2011

Mylan introduces generic version of Uroxatral for benign prostatic hyperplasia

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has shipped Alfuzosin Hydrochloride Extended-release Tablets, 10 mg.

12 Aug 2011

G-CSF therapy does not induce chromosomal instability in healthy stem cell donors

According to a study published in Blood, the Journal of the American Society of Hematology (ASH), researchers have reported that administration of granulocyte colony-stimulating factor (G-CSF), a drug that releases stem cells from the bone marrow into the blood, is unlikely to put healthy stem cell donors at risk for later development of abnormalities involving loss or gains of chromosomes that have been linked to hematologic disorders such as myelodysplastic syndromes (MDS) and acute myeloid leukemia.

12 Aug 2011

NSAIDs like ibuprofen slow the spread of breast cancers

Published online on Aug. 7, 2011, the journal Nature Medicine reports that non-steroidal anti-inflammatory drugs including ibuprofen reduce the severity of postpartum breast cancers in animal models.

12 Aug 2011

Endothelial progenitor cells may repair leaky blood-brain barrier

University of South Florida Department of Neurosurgery and Brain Repair faculty members have received a $2.6 million grant from the National Institutes of Health to investigate the potential for cells derived from human bone marrow to benefit post-stroke patients by repairing the blood-brain barrier.

12 Aug 2011